Post- ROSC adrenaline infusion rates and 30-day Mortality

• Research type

  Research Study

• Full title

  Is there an association between adrenaline infusion rates and 30-day Mortality in post - ROSC patients?

• IRAS ID

  261635

• Contact name

  John TAlbot

• Contact email

  j.r.talbot2@herts.ac.uk

• Sponsor organisation

  Univeristy Of Hertfordshire

• Duration of Study in the UK

  0 years, 5 months, 1 days

• Research summary

  Is there an optimum dosing strategy for adrenaline infusions in post-ROSC patients?

  Aims:

  To ascertain if there is association between infusion rates and 30-day mortality in post-ROSC patients treated by Critical Care paramedics from SECAmb.

  Objectives:
  • Determine if there a ceiling dose of adrenaline that does not confer a 30-day mortality benefit.
  • Evaluate if the patient’s cardio-vascular parameters adequately supported by adrenaline infusion. Do patients arrive at receiving centres adequately optimised with a MAP that is defined as perfusable to brain parenchyma?
  • Identify if there are certain sub-groups that may benefit from an adrenaline infusion.

• REC name

  North of Scotland Research Ethics Committee 2

• REC reference

  19/NS/0132

• Date of REC Opinion

  31 Jul 2019

• REC opinion

  Favourable Opinion